Utilization of Drugs with Approved Risk Evaluation and Mitigation Strategies (REMS) that Employ Elements to Assure Safe Use (ETASU): A Descriptive Analysis

In this request, we investigated utilization patterns of drugs with approved REMS (Risk Evaluation and Mitigation Strategies) that employ ETASU (Elements to Assure Safe Use).

This analysis includes two reports:

• Report 1: We executed this request on Merative™ MarketScan® Research Databases on May 5, 2021. The study period includes data from January 1, 2010 to September 30, 2019. Products assessed in this report include: collagenase clostridium histolyticum, isotretinoin, mycophenolate, lenalidomide, mifepristone, clozapine, phentermine/topiramate, eculizumab, natalizumab, and pomalidomide.
• Report 2: We executed this request on Merative™ MarketScan® Research Databases on October 15, 2021. The study period includes data from January 1, 2010 to September 30, 2020. Products assessed in this report include: alvimopan, testosterone undecanoate, panobinostat, teduglutide, alosetron, denosumab, vigabatrin, idelalisib, romiplostim, and olanzapine extended release.